Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Of Israel Licenses Lilly Gemzar Generic To APP Pharmaceuticals

This article was originally published in PharmAsia News

Executive Summary

Israel's Teva Pharmaceutical Industries contracted with APP Pharmaceuticals to make a generic version of Eli Lilly's Gemzar (gemcitabine) chemotherapy drug

You may also be interested in...



CMS Sets Insurers’ Deadlines To Comply With Final Health Care Price Transparency Rule

A final Medicare agency rule requiring insurers to reveal coverage prices for device-related procedures and tests will let consumers shop health services.

Court Ruling On Perrigo Appeal Of Nearly $2Bn Irish Tax Debt From Elan Deal Due With Q3 Results

Perrigo says on 4 November, Irish High Court will publish decision from a trial on the firm’s challenge to Irish Office of the Revenue Commissioners’ order to pay additional taxes from its acquisition of Elan. Perrigo moved its Q3 earnings briefing scheduled for 8 a.m. EDT the same day to 4:30 p.m.

Medicare Coverage Policy For COVID Drugs Underscores Importance Of Add-On Payments

Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel